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Abstract
A 54-year-old male consulted his general practitioner for increasing general anxiety and mild panic attacks despite effective
treatment for recurrent major depressive disorder, which included a ﬁsh oil supplement enriched in eicosapentaenoic acid
(EPA). The patient would awaken suddenly at night with shortness of breath and overwhelming worry. During the daytime, he
felt a general, nonspeciﬁc anxiety and frequently experienced sympathetic activation upon confronting routine challenges. He
also experienced dyspnea-induced feelings of panic. He reported that he stopped taking the ﬁsh oil supplements after several
more months of symptoms, and his anxiety and insomnia then largely disappeared. Several weeks later, he resumed
consumption of high-EPA ﬁsh oil at the prior dosage for 2 days. On both nights, the patient reported nighttime awakening
similar to the previous episodes, followed by daytime agitation. Since halting the ﬁsh oil supplements, the anxiety and
insomnia have not returned and his depression remains in remission.
INTRODUCTION
Long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFAs) are
the key ingredient in ﬁsh oil nutritional supplements and
evidence exists for their beneﬁt to both cardiovascular and psy-
chiatric health [1, 2]. Eicosapentaenoic acid (EPA), in particular,
has been implicated in improving mood disorders [3] and EPA-
enriched ﬁsh oil preparations are available. Sales in ﬁsh oil
supplements are in the billions of dollars (US) annually and
clinicians are increasingly likely to encounter patients who
are regularly taking these supplements. Adverse events related
to ﬁsh oil supplements are rarely reported and are described as
mild to moderate [2, 4].
CASE REPORT
The patient is a 55-year-old male employed as a professor in the
USA. At Age 42, he consulted his general practitioner for major
depressive disorder and was prescribed ﬂuoxetine, eventually
titrated to 40 mg. Pharmacotherapy combined with psychother-
apy generally relieved the worst episodes of depressive disorder,
but occasional relapses occurred for the next 10 years ormore. On
at least three occasions, the patient discontinued the ﬂuoxetine
when the depression was in remission, but symptoms returned
within a fewmonths each time and he resumed taking themedi-
cation. When he was 46, his general practitioner suggested add-
ing ﬁsh oil supplements to his regimen, particularly those that
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are enriched in EPA, at a dose of 2–3 g/day total lipids. He began
taking with morning meals two 1-g softgels per day of ﬁsh oil
that contained 6 : 1 EPA : DHA (docosahexaenoic acid, 500 mg
EPA per softgel). The patient reported that the supplements
seemed to noticeably relieve his depressive symptoms. He con-
tinued taking the same brand of high-EPA ﬁsh oil daily for 8
years (Metagenics ‘EPA 500 Concentrate’, formerly named ‘EPA :
DHA 6 : 1’) and while the depressive episodes did not completely
abate for severalmoreyears, they became shorter in duration and
more manageable. At Age 54, he had not experienced a signiﬁ-
cant relapse for over a year so he once again tapered off the ﬂuox-
etine. Of note, until this time he had not reported any signiﬁcant
anxiety symptoms. The patient exercises regularly and is in ex-
cellent health. Other signiﬁcant history includes asthma that is
well controlled and a cerebral aneurysm successfully treated
with endovascular coiling at Age 52. He uses an albuterol inhaler
for rare exacerbations of asthma, usually during upper respira-
tory tract infections, and takes a daily multivitamin. He ismedic-
ally literate and was cared for by two successive clinicians
(including L.B.B.) in the same medical ofﬁce for more than
20 years.
Sixmonths after stopping the ﬂuoxetine, the patient reported
that he had recently begun experiencing gradually worsening in-
somnia and general anxiety. He often awakened after 2 or 3 h of
sound sleep, sometimes with shortness of breath, and was then
unable to stop ruminating about possible catastrophic scenarios.
On some occasions, he felt so uncomfortable that he was forced
to arise to take up reading for an hour or more until he could re-
sume sleep. During the day, he sometimes felt overwhelmed and
would experience aﬂush of alarm, duringwhich his heart rate in-
creased and he began to perspire. On several occasions, exercise-
induced dyspnea triggered strong feelings of panic, most acutely
when bicycling at high elevations.
The patientmentioned that he had recently run out of his ﬁsh
oil supplements and seemed to feel better for the few days before
hewas able to purchase a new bottle. However, he felt that his re-
mission from depression was due in part to these supplements
so he continued to take them daily at the same dose. Hewas pre-
scribed lorazepam for his anxiety. After 6 more months of the
anxiety symptoms and insomnia, he stopped taking the ﬁsh oil
supplements altogether. Within days he felt noticeable relief.
He was much more at ease during the day and he could sleep
through the night without signiﬁcant awakenings. He stated
that after he had been largely anxiety-free for several weeks, he
experimented by resuming the supplements at the same dose
as previously for two mornings. On both subsequent nights,
and for one additional night, around 2 a.m. he suddenly became
fully awakeand couldnot resume sleep for at least anhour.While
he did not experience feelings of doom on these awakenings, his
thoughts were racing and he was again forced to arise and read
for an hour or more. On the following days, he felt agitated and
uneasy, which he said was typical when he did not get enough
sleep. Two days after the trial ended, he was sleeping well
again. At the time of this writing, the patient reports that he re-
mains largely free of anxiety and insomnia. He also reports that
he has not experienced signiﬁcant depressive symptoms either.
DISCUSSION
There is mounting but somewhat conﬂicting evidence that ﬁsh
consumption and a diet rich in long-chain omega-3 fatty acids
may decrease the risk of depression and anxiety [2, 3, 5–8]. Inter-
estingly, a large prospective cohort study found a U-shaped
relationship between ω-3 PUFA consumption and mental disor-
ders, with only the intermediate, but not the lowest and highest,
levels of ω-3 PUFA intake reducing the risk of depression and anx-
iety [5]. In another study, a high-EPA regimen reduced depressive
symptoms only in patients without comorbid anxiety [8]. The
consumption of ﬁsh oil supplements (up to 2 g total EPA + DHA
per day) has been recognized as safe and potentially beneﬁcial
by the American Heart Association and few adverse events
have heretofore been associated with their consumption [9].
However, individual responses to any substance can vary from
person to person. We provide here the ﬁrst report known to us
where omega-3 fatty acids are associated with an increase in in-
somnia and anxiety symptoms. Questions that arise from this
case include why the apparent earlier beneﬁts of the ﬁsh oil
changed to deleterious effects after resolution of the depression
and whether the latter effects were speciﬁc to high-EPA ﬁsh oil.
Perhaps the patient’s increasing age played a role in the change.
Consumers and clinicians should be aware of potential idiosyn-
cratic adverse events to any substance as widely consumed as
ω-3 PUFAs.
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